Menu
St. Louis biotech startup Wugen inks manufacturing deal, hires C-suite exec
St. Louis Business Journal, Nathan Rubbelke, March 2021
Read More
ARCHIVE
ARCHIVE
Wugen
Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer
ST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an exclusive license…
Read MoreWugen Announces the Appointment of Company’s Co-founder, Matt Cooper, Ph.D., as Chief Scientific Officer
ST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of the company’s co-founder, Matt Cooper, Ph.D., as…
Read More
St. Louis biotech startup Wugen inks licensing deal, hires new C-suite exec
St. Louis Business Journal, Nathan Rubbelke, February 2021
Read MoreWugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis
ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement…
Read MoreWugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs
ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of Jan Davidson M.D., Ph.D., as the company’s…
Read More
Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer
Biospace, Kate Goodwin, January 2021
Read MoreMultidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
Cancer Discovery, Berrien-Elliott et al, December 2020
Read MoreWugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline
ST. LOUIS, Nov. 19, 2020 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of…
Read MoreCAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Blood, Gang et al, November 2020
Read More
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design